ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Search Videos by Topic or Participant
Browse by Series:

Reimbursement Issues in Prostate Cancer, Part I

Panelists: Raoul S. Concepcion, MD, Urology Associates, PC; Steve Dobbs, Urologic Associates of Oklahoma; Bryan A. Mehlhaff, MD, Oregon Urology Institute;
Published: Friday, Feb 01, 2013
For High-Definition, Click
Raoul Concepcion, MD, FACS, begins the conversation by noting that urology as a business faces reimbursement and operational challenges.

Steve Dobbs, FACHE, says that his practice’s latest reimbursement issue has been with sipuleucel-T (Provenge), which is an expensive drug. According to Dobbs, the process to guarantee reimbursement is complicated. Initially, Dendreon completes the verification of benefits and the practice does a secondary review. Throughout the process, nurses are in contact with patients to notify them of any co-pay issues.

Administering sipuleucel-T has become such a large financial commitment, Dobbs says, that it’s now a separate line item in monthly board meetings. With regards to LHRH treatments, such as leuprorelin (Lupron), Dobbs’ practice reviews the reimbursement process on a quarterly basis.

The question many urologists face now is selecting the most appropriate treatment as new costly therapies gain approval. To solve this problem, medical experts discuss the clinical side of administering new drugs, while operations committees decides which agents to carry, and management teams negotiate costs and GPO relationship issues.

View part II of this conversation
Slider Left
Slider Right
For High-Definition, Click
Raoul Concepcion, MD, FACS, begins the conversation by noting that urology as a business faces reimbursement and operational challenges.

Steve Dobbs, FACHE, says that his practice’s latest reimbursement issue has been with sipuleucel-T (Provenge), which is an expensive drug. According to Dobbs, the process to guarantee reimbursement is complicated. Initially, Dendreon completes the verification of benefits and the practice does a secondary review. Throughout the process, nurses are in contact with patients to notify them of any co-pay issues.

Administering sipuleucel-T has become such a large financial commitment, Dobbs says, that it’s now a separate line item in monthly board meetings. With regards to LHRH treatments, such as leuprorelin (Lupron), Dobbs’ practice reviews the reimbursement process on a quarterly basis.

The question many urologists face now is selecting the most appropriate treatment as new costly therapies gain approval. To solve this problem, medical experts discuss the clinical side of administering new drugs, while operations committees decides which agents to carry, and management teams negotiate costs and GPO relationship issues.

View part II of this conversation
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x